Retractable Technologies (RVP) AI Stock Analysis

• Market Cap: $21.55M
• Dividend Yield: N/A
• Average Volume (3M): 153.51K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.51
• Revenue Growth: -0.95%
• EPS Growth: 58.17%
• Country: US
• Employees: 221
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.01
• Shares Outstanding: 29,937,159
• 10 Day Avg. Volume: 341,920
• 30 Day Avg. Volume: 153,511
• PEG Ratio: -0.03
• Price to Book (P/B): 0.24
• Price to Sales (P/S): 0.62
• P/FCF Ratio: -1.59
• Enterprise Value/Market Cap: 0.80
• Enterprise Value/Revenue: 0.45
• Enterprise Value/Gross Profit: -6.56
• Enterprise Value/Ebitda: -20.70
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: $0.77 ▲(6.53% Upside)

The score is held down primarily by weak profitability (negative margins) and negative operating cash flow despite low leverage. Technical indicators also lean bearish with the price below key moving averages and negative MACD. Valuation offers limited support because the negative P/E reflects ongoing losses, and no common dividend yield is provided.

Positive Factors

Revenue Growth

The return to revenue growth indicates a recovery in sales and potential market expansion, which can enhance long-term business stability and competitiveness.

Low Leverage

Minimal leverage risk provides financial flexibility and reduces vulnerability to economic downturns, supporting sustainable operations.

International Revenue Growth

Strong international growth expands market reach and diversifies revenue streams, reducing dependency on domestic markets and enhancing resilience.

Negative Factors

Negative Profit Margins

Persistently negative profit margins indicate operational inefficiencies and cost pressures, which could hinder long-term profitability and growth.

Negative Operating Cash Flow

Negative operating cash flow suggests liquidity issues and challenges in sustaining operations without external financing, impacting financial health.

Tariff Impact

Tariff impacts increase production costs and can strain profitability, necessitating strategic adjustments to maintain competitive pricing and margins.

Retractable Technologies Business Overview & Revenue Model

Company Description

Retractable Technologies, Inc. designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession in the United States, rest of North and South America, and internationally. It offers VanishPoint insulin syringes; tuberculin, insulin, and allergy antigen syringes; small diameter tube adapters; blood collection tube holders; allergy trays; IV safety catheters; Patient Safe syringes and Luer Caps; VanishPoint blood collection sets; EasyPoint needles; and VanishPoint autodisable syringes. The company distributes its products through general line and specialty distributors, as well as through international distributors; and a direct marketing network. Retractable Technologies, Inc. was incorporated in 1994 and is headquartered in Little Elm, Texas.

How the Company Makes Money

Retractable Technologies generates revenue primarily through the sale of its retractable syringes and safety needle products. The company sells these products directly to healthcare providers and distributors, establishing long-term contracts and partnerships that ensure a steady stream of orders. Additionally, RVP benefits from government contracts and participation in group purchasing organizations, which enable it to reach a broader customer base. The company may also explore partnerships with other healthcare firms to expand its product offerings or enter new markets, contributing to its overall earnings.

Retractable Technologies Financial Statement Overview

Summary

Retractable Technologies faces challenges with profitability and cash flow generation, despite maintaining a strong balance sheet with low leverage. Revenue growth has been inconsistent, and the company needs to address operational inefficiencies to improve margins and cash flow stability. The financial health is moderate, with potential risks from ongoing losses and cash flow constraints.

Income Statement

Retractable Technologies has experienced significant revenue volatility, with a recent TTM revenue growth of 13.09% following a previous decline. However, profitability metrics are concerning, with negative gross and net profit margins in the TTM period, indicating operational challenges. The EBIT and EBITDA margins have also deteriorated, reflecting ongoing cost pressures.

Balance Sheet

The company maintains a strong balance sheet with a low debt-to-equity ratio of 0.015, indicating minimal leverage risk. However, the negative return on equity in the TTM period suggests inefficiencies in generating returns from shareholders' equity. The equity ratio remains stable, highlighting a solid capital structure.

Cash Flow

Cash flow performance is mixed, with a positive free cash flow growth rate of 10.09% in the TTM period. However, negative operating cash flow and a high free cash flow to net income ratio indicate potential liquidity issues. The company needs to improve its cash generation capabilities to support operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	38.16M	33.05M	43.60M	94.82M	188.38M	81.86M
Gross Profit	-2.62M	-1.03M	9.11M	28.25M	95.35M	37.01M
EBITDA	-829.42K	4.17M	-1.24M	9.94M	76.44M	27.17M
Net Income	-8.74M	-11.89M	-7.01M	5.08M	56.06M	24.22M
Balance Sheet
Total Assets	147.09M	160.72M	179.67M	210.74M	213.15M	104.97M
Cash, Cash Equivalents and Short-Term Investments	33.05M	44.56M	47.29M	49.38M	42.43M	25.65M
Total Debt	1.07M	1.23M	1.54M	2.92M	4.24M	3.74M
Total Liabilities	70.62M	73.55M	80.38M	104.21M	113.98M	55.09M
Stockholders Equity	76.47M	87.17M	99.29M	106.54M	99.17M	49.88M
Cash Flow
Free Cash Flow	-13.55M	-13.00M	1.91M	-61.95K	-25.57M	-2.05M
Operating Cash Flow	-12.04M	-11.56M	2.77M	16.77M	32.79M	19.00M
Investing Cash Flow	8.78M	3.66M	-10.76M	-31.20M	-63.04M	-19.33M
Financing Cash Flow	-551.50K	-535.43K	941.64K	4.99M	41.84M	11.96M

Retractable Technologies Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.72
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RVP, the sentiment is Negative. The current price of 0.72 is below the 20-day moving average (MA) of 0.79, below the 50-day MA of 0.81, and below the 200-day MA of 0.77, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 28.47 is Positive, neither overbought nor oversold. The STOCH value of 23.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RVP.

Retractable Technologies Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
STXS	62 Neutral	$256.64M	-9.78	-170.24%	―	19.61%	-3.42%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
RVP	48 Neutral	$21.55M	-3.23	-8.05%	―	-0.95%	58.17%
OSUR	47 Neutral	$193.32M	-3.32	-15.30%	―	-43.95%	-620.21%
SMTI	42 Neutral	$206.86M	-5.33	-27.19%	―	30.55%	-340.19%
MLSS	42 Neutral	$22.76M	-3.50	-136.47%	―	0.59%	-39.76%

Retractable Technologies Corporate Events

Retractable Technologies Declares Dividend on Convertible Preferred Shares

On December 30, 2025, Retractable Technologies announced that it declared a dividend for holders of its Series II and Series III Class B Convertible Preferred Stock. The dividend declaration affects this specific class of preferred shareholders and reflects a capital allocation decision that may influence investor returns and perceptions of the company’s treatment of its preferred equity holders.

The most recent analyst rating on (RVP) stock is a Hold with a $0.80 price target. To see the full list of analyst forecasts on Retractable Technologies stock, see the RVP Stock Forecast page.

Retractable Technologies Reports Q3 2025 Financial Results

On November 14, 2025, Retractable Technologies reported its financial results for the third quarter of 2025, showing net sales of $10.1 million and an operating loss of $3.7 million, compared to $10.3 million in sales and a $5.1 million loss in the same period last year. The company has been impacted by tariffs on imported products, leading to increased domestic production, which now accounts for 38.3% of its manufacturing. Despite a decrease in overall unit sales, the company improved its gross margin due to a favorable product mix and reduced tariff costs. International revenues increased by 25% for the quarter, although the average selling price declined. Retractable also received an Innovative Technology designation from Vizient®.

The most recent analyst rating on (RVP) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Retractable Technologies stock, see the RVP Stock Forecast page.